Valuation: Omeros Corporation

Market Cap 1.41B 1.24B 1.17B 1.06B 2B 135B 2.01B 14.03B 5.41B 68.91B 5.28B 5.17B 221B P/E 2026 *
21.4x
P/E 2027 * 18.4x
Enterprise Value 1.41B 1.24B 1.17B 1.06B 2B 135B 2.01B 14.03B 5.41B 68.91B 5.28B 5.17B 221B EV / Sales 2026 *
11x
EV / Sales 2027 * 6.36x
Free-Float
95.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.93%
1 week+4.11%
Current month+2.45%
1 month+3.44%
3 months+122.03%
6 months+94.84%
Current year+12.08%
1 week 19
Extreme 19
20.97
1 month 16.5
Extreme 16.5001
21.24
Current year 6.7
Extreme 6.7023
21.24
1 year 4.06
Extreme 4.055
21.24
3 years 0.92
Extreme 0.92
21.24
5 years 0.92
Extreme 0.92
21.24
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 15/06/1994
Director of Finance/CFO 62 29/06/2024
Chief Tech/Sci/R&D Officer 70 31/10/2019
Director TitleAgeSince
Chairman 67 15/06/1994
Director/Board Member 86 31/12/1994
Director/Board Member 72 31/12/1994
Date Insider Type Main position Quantity % Market Cap. Importance
23/09/26 Exercice

Chief Financial Officer

30,000 0.0414%
31/08/26 Exercice

General Counsel

75,000 0.1036%
27/08/26 Exercice

Director

30,000 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
-0.93%+4.11%+331.61%+559.25% 1.41B
-0.70%-4.35%+56.10%+86.42% 71.81B
+0.45%-2.26%+38.36%+87.74% 60.06B
+0.19%+0.94%+36.97%+21.32% 27.93B
-1.73%-4.44%-15.62%+348.87% 25.7B
-0.51%+0.58%+0.50%-3.39% 24.89B
+0.65%+2.52%+25.89%-6.99% 20.92B
+3.46%+3.91%+158.90%+337.81% 15.04B
+0.48%+2.50%+50.23%+161.95% 14.46B
+3.91%-4.56%-2.71%+506.41% 13.87B
Average +0.53%-0.45%+68.02%+209.94% 27.61B
Weighted average by Cap. +0.18%-0.52%+40.07%+130.54%

Financials

2026 *2027 *
Net sales 128M 112M 106M 96.37M 181M 12.24B 183M 1.27B 491M 6.25B 479M 468M 20.05B 221M 195M 184M 167M 314M 21.24B 317M 2.21B 851M 10.84B 831M 813M 34.8B
Net income 64.97M 57.28M 54.15M 49.11M 92.16M 6.23B 93M 648M 250M 3.18B 244M 239M 10.22B 84.8M 74.76M 70.69M 64.1M 120M 8.14B 121M 846M 326M 4.15B 318M 311M 13.34B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
29/09/26 US$19.25 -0.93% 841,373
28/09/26 US$19.43 -3.24% 1,026,395
25/09/26 US$20.08 -0.25% 942,084
24/09/26 US$20.13 -2.94% 909,690
23/09/26 US$20.74 -1.47% 1,349,574
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
19.43USD
Average target price
27.50USD
Spread / Average Target
+41.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock